Top Medical News
OSA tied to coronary collateral vessel development in STEMI patients
Patients with ST-segment elevation myocardial infarction (STEMI) are more likely to develop a coronary collateral vessel (CCV) in the presence of obstructive sleep apnoea (OSA), according to a study.
Coronavirus surrogates may stay on meat, fish in cold storage for up to a month
Audrey Abella, 2 days ago
Surrogates of SARS-CoV-2* – a lipid enveloped RNA bacteriophage (Phi6) and two animal coronaviruses (CoVs; MHV and TGEV**) – survived in cold-storage temperatures for 30 days, a study finds, highlighting the risk of viral survival on food products and potential transmission on humans upon consumption.
ESTRO: weight loss death risk lung cancer patients radiotherapy
2 days ago
Female smokers with early natural menopause are at high risk of developing malignant and nonmalignant lung diseases, as well as of death, as reported in a study.
Poor cardiorespiratory fitness ups risk of mortality
3 days ago
An inverse, independent, and graded association exists between cardiorespiratory fitness (CRF) and mortality risk across the spectra of age, sex, and race, a recent study has found. In addition, there is no risk increase seen among extremely fit individuals.
Double-dose tigecycline more effective than standard doses, but with potentially more side effects
6 days ago
Twice-daily 100-mg doses of tigecycline leads to better clinical response, bacterial clearance, and survival in intensive care unit patients with ventilator-associated pneumonia, reports a recent meta-analysis. However, such a double-dose regimen may also show higher treatment toxicities.
Wearable device as good as polysomnography in estimating oxygen saturation during sleep
Tristan Manalac, 01 Aug 2022
A wrist-worn reflectance-based pulse oximeter can measure oxygen saturation during sleep with reasonable accuracy and small error, according to a recent study.
Special Reports
Product Highlight - Bilaxten ODT
16 Mar 2022
Bilastine 10 mg orodispersible tablet
Kids hard-hit by Delta; which ART performs best?
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Rapid antigen test: Don’t let perfect be the enemy of good
Pearl Toh, 23 Oct 2021
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
ID NOW rapid molecular assay an effective COVID-19 test for kids
Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Antigen rapid tests: The new COVID-19 strategy moving forward?
Roshini Claire Anthony, 31 Jul 2021

Same-day pre-event screening for SARS-CoV-2 using antigen-detecting rapid diagnostic tests (Ag-RDT) may enable the resumption of large-scale indoor events which were halted or had their attendance capacity reduced during the COVID-19 pandemic, according to a study from Spain presented at ECCMID 2021.

Combined Ag/Ab rapid testing boosts case-finding in COVID-19
Elvira Manzano, 29 Jul 2021
A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.
Conference Reports
Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma
Roshini Claire Anthony, 27 Jun 2022

Adolescents and adults with severe uncontrolled asthma while on inhaled corticosteroids (ICS) had greater responses to the human monoclonal antibody tezepelumab than placebo, according to prespecified exploratory results of the phase III NAVIGATOR trial.

COPD tied to earlier lung cancer diagnosis
Audrey Abella, 27 Jun 2022
Chronic obstructive pulmonary disease (COPD) is associated with an earlier diagnosis of lung cancer, according to a cross-sectional, real-world study.
Fixed-dose albuterol/budesonide an effective rescue med in moderate-to-severe asthma
Roshini Claire Anthony, 15 Jun 2022

A fixed-dose combination of albuterol and budesonide, delivered as needed, reduced the risk of severe exacerbations in patients with moderate-to-severe asthma inadequately controlled with corticosteroid maintenance therapy, according to results of the phase III MANDALA trial presented at ATS 2022.

Novel PDE4 inhibitor slows IPF progression
Elaine Soliven, 10 Jun 2022
Treatment with BI 1015550, a novel investigational phosphodiesterase 4 (PDE4) inhibitor, slows lung function decline in patients with idiopathic pulmonary fibrosis (IPF) with or without background antifibrotic therapy, according to a 12-week phase II trial data presented at ATS 2022.
Microwave ablation: a better treatment alternative for NSCLC?
Audrey Abella, 08 Jun 2022
In patients with non-small-cell lung cancer (NSCLC), image-guided thermal ablation (IGTA) via microwave ablation (MWA) appears to deliver better survival benefit compared with another IGTA subtype, radiofrequency ablation (RFA), or stereotactic body radiation therapy (SBRT), according to a systematic review and meta-analysis presented at ATS 2022.
Weight loss intervention may improve COPD outcomes
Roshini Claire Anthony, 07 Jun 2022

In addition to cardiometabolic benefits, a lifestyle intervention aimed at weight loss in patients with chronic obstructive pulmonary disease (COPD) who are overweight or obese may reduce COPD symptoms, according to results of the INSIGHT COPD trial presented at ATS 2022.

Imatinib may reduce mortality in hospitalized COVID-19 patients
Roshini Claire Anthony, 06 Jun 2022

The tyrosine kinase inhibitor imatinib may reduce mortality in patients hospitalized with severe COVID-19, according to follow-up results of the CounterCOVID study presented at ATS 2022.